Cite
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
MLA
Herrera, Alex F., et al. “Risk Profiling of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma by Measuring Circulating Tumor DNA.” Blood Advances, vol. 6, no. 6, Mar. 2022, pp. 1651–60. EBSCOhost, https://doi.org/10.1182/bloodadvances.2021006415.
APA
Herrera, A. F., Tracy, S., Croft, B., Opat, S., Ray, J., Lovejoy, A. F., Musick, L., Paulson, J. N., Sehn, L. H., & Jiang, Y. (2022). Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Advances, 6(6), 1651–1660. https://doi.org/10.1182/bloodadvances.2021006415
Chicago
Herrera, Alex F., Samuel Tracy, Brandon Croft, Stephen Opat, Jill Ray, Alex F. Lovejoy, Lisa Musick, Joseph N. Paulson, Laurie H. Sehn, and Yanwen Jiang. 2022. “Risk Profiling of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma by Measuring Circulating Tumor DNA.” Blood Advances 6 (6): 1651–60. doi:10.1182/bloodadvances.2021006415.